Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble

Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Rachel Cohrs, STAT’s Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing — and what could still stand in their way. We also discuss the latest news in the life sciences, including some hotly anticipated data from Alnylam Pharmaceuticals, a $4 billion buyout deal, and other surprisingly good news for biotech.

For more on what we cover, here’s the latest on drug pricing legislation; here’s the news from Alnylam; here’s more on Sarepta Therapeutics; here’s the latest from Amgen; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].